DRUG UTILIZATION STUDY OF CHEMOTHERAPY IN OVARIAN CANCER PATIENTS (A Study at Dr. Ramelan Naval Hospital Surabaya)

ABSTRACT

DRUG UTILIZATION STUDY OF CHEMOTHERAPY IN OVARIAN CANCER PATIENTS

(A Study at Dr. Ramelan Naval Hospital Surabaya)

Ovarian cancer is the most common cause of gynecologic cancer death and the fifth common cause of cancer death among women. Three major types of ovarian cancer are Coelomic Epithelial Origin (CEO), Germ Cell Origin (GCO), and Gonadal-Stromal Origin. Chemotherapy is treatment for cancer with spreading metastasis. The goals of chemotherapy are to treat the symptomps of the disease and lengthening survival time. A Drug Utilization Study (DUS) of chemotherapy in ovarian cancer patients has been conducted at Dr. Ramelan Naval Hospital Surabaya. The methode of this study was non-experimental and descriptive. The collection of the data has been done retrospectively using the medical record of the individual patient who received chemotherapy. The results of the study showed: (1) Prevalence of ovarian cancer was most occurred to women in ages 51-60 years old (2) the most prevalence type of ovarian cancer patients was CEO (52%) (3) the highest prevalence stage of ovarian cancer patients was IIIC (4) the regiments of chemotherapy that most used were Cisplatin-Cyclophosphamide (47,4%), then Carboplatin-Paclitaxel (36,8%) (5) drugs used for the side effects of chemotherapy were: antiemetic and corticosteroid. The chemotherapy drugs used for patients were confirmed with the guideline.

Keywords : chemotherapy, ovarian cancer, Drug Utilization Study (DUS), descriptive-retrospective study.